Clinical Trial Update: Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating talazoparib in combination with carboplatin for recurrent high-grade glioma with DDR deficiency has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Talazoparib (talazoparib)

Snippet

Sponsor: The University of Hong Kong | Conditions: Recurrent Glioma, Recurrent Glioblastoma | Phase 2 | Status: COMPLETED